Evidence map›Paper›PMID 39478665›Full record

ReviewJournal of medicinal chemistry2024

Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition.

Xin Li, Yongcheng Song

Abstract readReview
In one paragraph

Review in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Funding

Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric LeukemiaR01CA266057 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SONG, YONGCHENG · 2022 to 2025
$1.7M
Novel small-molecule inhibitors of SARS-CoV-2 proteaseR21AI159323 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI SONG, YONGCHENG · 2021 to 2021
$440k
NCI NIH HHS R01 CA266057NIAID NIH HHS R21 AI159323NIH RP220232
6 · The paper itself

Abstract

Severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is highly contagious and caused a catastrophic pandemic. It has infected billions of people worldwide with >6 million deaths. With expedited development of effective vaccines and antiviral drugs, there have been significantly reduced SARS-CoV-2 infections and associated mortalities and morbidities. The virus is closely related to SARS-CoV, which emerged in 2003 and infected several thousand people with a higher mortality rate of ∼10%. Because of continued viral evolution and drug-induced resistance, as well as the possibility of a new coronavirus in the future, studies for new therapies are needed. The viral methyltransferases play critical roles in SARS coronavirus replication and are therefore promising drug targets. This review summarizes the function, structure and inhibition of methyltransferases of SARS-CoV-2 and SARS-CoV. Challenges and perspectives of targeting the viral methyltransferases to treat viral infections are discussed.

Indexed as

Antiviral AgentsDrug DiscoveryMethyltransferasesSARS-CoV-2Severe acute respiratory syndrome-related coronavirusCOVID-19COVID-19 Drug TreatmentEnzyme InhibitorsHumansViral Nonstructural ProteinsAntiviral AgentsEnzyme InhibitorsMethyltransferasesViral Nonstructural Proteins

Identifiers

PMID39478665
PMCPMC11787806

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.